Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 5 versus EVEKEO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 5 versus EVEKEO ODT.
DYANAVEL XR 5 vs EVEKEO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CNS stimulant; blocks reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
20 mg orally once daily in the morning; may increase by 10 mg weekly based on response; maximum 60 mg/day.
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
None Documented
None Documented
Terminal elimination half-life for d-amphetamine is 10-13 hours; for l-amphetamine, 13-16 hours. Clinical context: Twice-daily dosing may be required for sustained effect.
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
Renal: ~90% as unchanged amphetamine and metabolites. Fecal: minimal (<5%).
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Category C
Category C
CNS Stimulant
CNS Stimulant